stockrowPrecision BioSciences, Inc.
DTIL Healthcare Biotechnology
Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024.
- Revenue
- +37,272.4%
- EPS
- +85.0%
- Free cash flow
- −0.52%
- Total debt
- +0.22%
Quarter to September 2026, against a year earlier
Follow DTIL
Alert me
Precision BioSciences, Inc. (DTIL) EV/Sales
As of 6 November 2026, Precision BioSciences, Inc. (DTIL) trades at a EV/Sales of 5.2×. Over the past ten years it has ranged from −4.2× (March 2023) to 114× (October 2025); the current reading is higher than 63% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −1.2× | — |
| FY2024 | −0.6× | — |
| FY2023 | −1.5× | — |
| FY2022 | −2.6× | — |
| FY2021 | 2.5× | (82.54%) |
| FY2020 | 14.5× | (19.70%) |
| FY2019 | 18.1× | 14.55% |
| FY2018 | 15.8× | 0.00% |
| FY2017 | 15.8× | 0.00% |
| FY2016 | 15.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 1.3× | — |
| Dec 2025 | −1.2× | — |
| Sep 2025 | 61.2× | 1,086.93% |
| Jun 2025 | 5.2× | — |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FULC Fulcrum Therapeutics, Inc. compare | −0.4× |
| TTRX Turn Therapeutics Inc. compare | n/m |
| VOGX Vogenx Inc compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. compare | 2.0× |
| DTIL Precision BioSciences, Inc. | 5.2× |
| PRLD Prelude Therapeutics Incorporated compare | 9.0× |
| OCGN Ocugen, Inc. compare | 48.8× |
| SABS SAB Biotherapeutics, Inc. compare | 85.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)